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a b s t r a c t
Background: The development of abuse deterrent formulations is one strategy for reducing prescription opioid misuse and abuse. A putative abuse deterrent formulation of oxycodone extended release
(OxyContin® ) was introduced in 2010. Early reports demonstrated reduced abuse and diversion, however, an analysis of social media found 32 feasible methods to circumvent the abuse deterrent mechanism.
We measured trends of diversion, abuse and street price of OxyContin to assess the durability of the initial
reduction in abuse.
Methods: Data from the Poison Center Program, Drug Diversion Program, Opioid Treatment Program,
Survey of Key Informant Patients Program and StreetRx program of the Researched Abuse, Diversion, and
Addiction-Related Surveillance (RADARS® ) System were used. The average quarterly rates of abuse and
diversion for OxyContin were compared from before reformulation to the rate in second quarter 2015.
Rates were adjusted for population using US Census data and drug availability.
Results: OxyContin abuse and diversion declined signiﬁcantly each quarter after reformulation and persisted for 5 years. The rate of abuse of other opioid analgesics increased initially and then decreased,
but to lesser extent than OxyContin. Abuse through both oral and non-oral routes of self-administration
declined following the reformulation. The geometric mean difference in the street price of reformulated
OxyContin was 36% lower than the reformulated product in the year after reformulation.
Discussion: Despite methods to circumvent the abuse deterrent mechanism, abuse and diversion of OxyContin decreased promptly following the introduction of a crush- and solubility- resistant formulation
and continued to decrease over the subsequent 5 years.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Misuse and abuse of prescription analgesics is a major health
problem. In 2014, there were 2.2 million current nonmedical
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users of prescription pain relievers in the United States (Center
for Behavioral Health Statistics and Quality, 2015). More than
16,000 deaths were attributed to prescription pain relievers in 2013
(Hedegaard et al., 2015). In 2011, the Ofﬁce of National Drug Control Policy issued a national strategy to combat prescription drug
abuse (United States Ofﬁce of National Drug Control Policy, 2011).
The strategy included several components, including research into
formulations with abuse deterrent properties. In 2015, the FDA
released guidance regarding the development of abuse deterrent
formulations (United States Food and Drug Administration, 2015).
One speciﬁed property was physical-chemical barriers, which
involves making a tablet difﬁcult to crush; thereby inhibiting use
through chewing, nasal insufﬂation, injection, or smoking.

http://dx.doi.org/10.1016/j.drugalcdep.2016.09.018
0376-8716/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
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OxyContin® is an extended release (ER) formulation of oxycodone that became a popular drug of abuse (United States
Food and Drug Administration, 2001). In 2010, the manufacturer
introduced a reformulated tablet that was difﬁcult to crush and
formed a viscous hydrogel to make snorting and injection difﬁcult (Alexander et al., 2014). The FDA approved new labeling
describing the abuse deterrent features and subsequently denied
applications from other oxycodone ER formulations without abuse
deterrent features (United States Food and Drug Administration,
2013). Reformulated OxyContin and its authorized generic products remain the only form of oxycodone ER marketed in the United
States.
Initial reports suggested that reformulation reduced the abuse
and diversion of OxyContin (Severtson et al., 2013; Butler et al.,
2013). However, a review of internet forums found 32 feasible
recipes to overcome the tamper resistant properties (McNaughton
et al., 2014). Previous research suggests that many abusers switch
to other products, particularly immediate release oxycodone and
hydromorphone (Cicero et al., 2012; Havens et al., 2014). If methods to circumvent abuse deterrent methods became widespread,
abuse and diversion could return to high rates. OxyContin represents a sentinel opportunity to assess the durability of the strategy
of physical-chemical abuse deterrent properties.
We analyzed rates of opioid analgesic abuse and diversion for
the 5 years following reformulation to determine whether initial
reductions in OxyContin abuse persisted despite the availability of
methods to circumvent the abuse deterrent properties.
2. Methods
2.1. Data sources
The Researched, Abuse, Diversion, and Addiction Related
Surveillance (RADARS® ) System provides post-marketing surveillance of prescription medication abuse and diversion to pharmaceutical companies, regulatory agencies, and policy making
organizations. The System is comprised of multiple surveillance
programs that independently gather data on prescription drug
abuse from different perspectives. The RADARS System is owned
and operated by the Denver Health and Hospital Authority, which
operates the public hospital for the city and county of Denver. The
system is supported by subscriptions from pharmaceutical companies that produce prescription opioids or stimulants, which use the
data for risk management and postmarketing surveillance reporting to the Food and Drug Administration.
The Poison Center Program studies acute health events by
recording the substances involved in poison center cases classiﬁed
as intentional abuse. The Drug Diversion Program measures drug
diversion by recording the drugs involved in cases opened by law
enforcement drug diversion investigators. The Opioid Treatment
Program and the Survey of Key Informants’ Patients Program both
query new patients entering substance-abuse treatment about
medications that they have abused. The StreetRx Program utilizes
a crowdsourcing website that gathers street price data for drugs
using a publically-accessible website. Further information on each
surveillance program has been published (Dart et al., 2015).
2.2. Deﬁnitions
In the Poison Center Program, a case involves an individual
exposure contact in which the case was coded to the category of
Intentional Abuse, which is deﬁned as an exposure resulting from
the intentional improper or incorrect use of a substance where
the victim was likely attempting to gain a euphoric or other psychotropic effect (American Association of Poison Control Centers,

2014). Poison Center Program mentions are the total number of
active pharmaceutical ingredient (API) reports involved for all cases
within a deﬁned group. Mentions differ from cases in that an individual (case) may be exposed to more than one product (mention).
There is an average of 1.04 opioid mentions per case.
In the Opioid Treatment and Survey of Key Informants’ Patients
programs, a case is deﬁned as a survey respondent endorsing the
abuse of a prescription opioid in the preceding 30 days. In these
programs, mentions are the total number of endorsements. The
average number of mentions per case is 1.68 for the Opioid Treatment Program and 1.83 for the Survey of Key Informant Patients
Program.
In the Drug Diversion Program, a case is deﬁned as an investigation, which can have one or more mentions (drugs involved in the
case). Drug diversion ofﬁcers submit data quarterly on the number
of new cases involving prescription products within their jurisdiction. These cases arise from arrests, street buys and sales by law
enforcement agents, and investigation of prescribers, among other
reasons.
In StreetRx, users enter the price of drugs they paid or heard
was paid from an extensive list of drugs provided on the website
(http://streetrx.com). StreetRx submissions from the United States
for OxyContin that included a price paid, dosage strength, and date
were included.
Quarterly population rates were calculated by dividing the total
number of cases by the sum of the population in the 3-digit ZIP
codes covered by each program using 2010 US census results, thus
allowing for each individual to contribute once to the numerator
and once to the denominator within each drug group. In contrast, rates adjusted for prescriptions dispensed are calculated by
dividing the sum of the mentions by the sum of the projected prescription volume in the 3-digit ZIP codes covered by each program.
For mention based rates, such as prescription rates, a single individual may be counted multiple times in both the numerator and
denominator. Quarterly prescription rates were calculated using
the projected number of prescriptions dispensed as provided using
a proprietary method by IMS Government Solutions, Inc., a subsidiary of IMS Health, Inc. (Danbury, CT) for each drug. Due to
preferences indicated by US FDA, we also calculated rates using the
concept of “extended dosage units,” which is deﬁned as individual
tablets or capsules dispensed at retail pharmacies (IMS Government Solutions, Danbury CT; Secora et al., 2014)
2.3. Analysis procedures
Generalized linear modeling was used to compare the difference in mean population intentional abuse and diversion rates in
the year prior to the reformulation (Baseline period: July 2009
through June 2010) to the estimated rate for 2015 quarter (2Q,
April 2015 through June 2015) based upon the trend (slope) of
the post-reformulation rates. Changes in the OxyContin rate were
compared to changes for the Other Opioid group (oral dosage
forms of opioid analgesics: hydrocodone, hydromorphone, morphine, oxymorphone, tramadol, tapentadol, and immediate release
oxycodone). The group was chosen because published evidence
indicates that abusers switch to a variety of other prescription
opioid analgesics, therefore, we combined the oral dosage unit formulation of those products into a single comparison group (Cicero
et al., 2012; Havens et al., 2014). Oxymorphone data were only
available from 2011 in the Drug Diversion program and from 2011
Q3 in the Opioid Treatment and Survey of Key Informants’ Patients
Programs. A Poisson regression analysis was used to calculate the
expected rates and 95% conﬁdence bands for each time period
and drug group. A drug group speciﬁc dispersion parameter was
included in the model to allow for unequal variances and overdispersion. The six month period encompassing the introduction of

CI − conﬁdence intervals.
IR − immediate release formulation.
ER − extended release formulation.
Other Opioid Group = (IR oxycodone, IR and ER hydrocodone, IR and ER morphine, IR and ER hydromorphone, IR and ER tramadol, IR and ER oxymorphone, and IR and ER tapentadol).
a
Signiﬁcantly different from other opioids, p < 0.0001.
b
Signiﬁcantly different from other opioids, p < 0.001.
c
Signiﬁcantly different from other opioids, p < 0.01.

−2.6c −4.0, −1.1
−0.3 −1.1, 0.5
−34.8b −48.4, −17.7
10.8 −5.1, 29.5
0.323
0.065
−4.0c −5.5, −2.4
−1.5 −2.3, −0.7
0.122
0.441
Survey of Key Informants’ Patients
0.265
OxyContin
Other Opioid Group
0.475

−53.9a −64.1, −40.7
−7.2 −19.4, 6.9

0.495
0.058

−8.2a −10.4, −6.0
−3.2 −4.2, −2.3
−72.8a −80.6, −62.0
−30.9 −40.4, −19.8
0.261
0.080
−9.4a −11.1, −7.6
−3.5 −4.3, −2.7
0.100
0.670
Opioid Treatment Program
OxyContin
0.574
Other Opioid Group
0.986

−82.6a −86.7, −77.1
−32.0 −40.1, −22.9

0.962
0.116

−8.3a −10.6, −6.1
−2.7 −3.6, −1.8
−85.8a −89.7, −80.5
−31.7 −40.3, −21.8
0.055
0.058
−8.9a −11.2, −6.5
−2.8−3.7 to −1.9
0.021
0.983
0.195
1.344
Drug Diversion Program
OxyContin
Other Opioids

−89.4a −92.6, −85.2
−26.8 −36.0, −16.3

0.386
0.085

−5.0b −6.1, −3.8
−2.6 −3.0, −2.2
−62.3a −67.9, −55.6
−33.7 −38.1, −29.0
0.038
0.015
−6.1a −7.1, −5.1
−3.1 −3.5, −2.6
0.014
0.260
0.056
0.387
Poison Center Program
OxyContin
Other Opioid Group

−75.0a −78.4, −71.1
−32.8 −37.4, −27.9

0.100
0.023

Average Quarterly
Rate change (%)
Total change
2015-Q2 (%) 95%
CI
Projected rate in
2015-Q2 per 1000
prescriptions
dispensed
Baseline rate per
1000 prescription
dispensed
Quarterly Rate
change (%)
Total change
2015-Q2 (%) 95%
CI
Projected rate in
2015-Q2 per
100,000
population
Baseline rate per
100,000
population

Population Adjusted

Table 1
Change in rate of abuse and diversion for prescription opioids after reformulation of OxyContin.

Prescription Adjusted
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reformulated OxyContin was considered a transition period and
excluded from the analysis. Therefore, quarterly rates from July,
2009 to June, 2010 (before reformulation) and rates from January,
2011 to June, 2015 (after reformulation) were used in all analyses.
The route of administration for poison center cases was compared before and after introduction of reformulated OxyContin
using generalized linear modeling. Comparisons were conducted
by route of administration and by time period. Oral routes (swallowing tablet whole, dissolving in mouth, and chewing then
swallowing) were compared to non-oral routes (injection or
inhalation, which is primarily insufﬂation). A speciﬁc dispersion
parameter for route of OxyContin administration was included
in the model. Product speciﬁc route information was collected
beginning in January, 2010; therefore the analysis period includes
quarterly rates from January, 2010 to June, 2010 (before reformulation) and January, 2011 to June, 2015 (after reformulation).
Street price data were normalized by the milligram strength of
the unit purchased, providing price per milligram as the analysis
metric. The price data from the StreetRx Program were positively
skewed, therefore, in multivariate models the price data were
log-transformed and regressed on a covariate for year and formulation. This calculation provides a difference in the geometric mean
price adjusted for time. Geometric means were used because they
approximate the median and are considered more representative
than arithmetic means in economic research.

3. Results
3.1. Number of prescriptions dispensed
Prescriptions dispensed for OxyContin decreased from
1,608,747 in second quarter 2010 (2010-Q2) to 1,211,593 in
2015-Q2, a 25% reduction (Fig. 1). In contrast, the Other Opioid
group increased 7% from 50,814,374 to 54,567,288 during the
same period. Except for hydrocodone combination formulations
and OxyContin, prescriptions dispensed increased for each opioid
analgesic.
The decrease in prescriptions was biphasic. In the 6 month
period of 2010-Q3 through 201-Q1, OxyContin prescriptions dispensed declined 13.9%, while prescriptions for Other Opioids
increased 5.9%. Subsequently, for the period from 2011-Q2 through
2015-Q2, OxyContin declined 12.9% and Other Opioids declined
5.9%.

3.2. Poison center program intentional abuse
A total of 2159 OxyContin cases and 19,815 Other Opioid cases
were received during the study period. The population adjusted
rate for OxyContin decreased −75.0% (95% CI: −78.4, −71.1) after
reformulation (Table 1, Fig. 2A), from baseline to 2015-Q2. This was
the greatest decrease among the opioids and signiﬁcantly larger
than the Other Opioid group (-32.8%, 95% CI: −37.4, −27.9). The rate
for OxyContin declined −6.1% (95% CI: −7.1% to −5.1%) each quarter
on average following reformulation, which was greater than the
Other Opioid group) (−3.1%, 95% CI: −3.5, −2.6).
The prescription adjusted OxyContin rate decreased −62.3%
(95% CI: −67.9, −55.6) following reformulation (Table 1, Fig. 2B)
from baseline to 2015-Q2, which was the greatest among the opioid
categories and signiﬁcantly greater than the Other Opioid group (33.7%, 95% CI: −38.1, −29.0). OxyContin rates declined −5.0% (95%
CI: −6.1%, −3.8) per quarter on average following reformulation,
which was signiﬁcantly greater than the Other Opioid group (−2.6%,
95% CI: −3.0, −2.2).
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Fig. 1. Number of opioid analgesic prescriptions dispensed in the United States, April 1, 2009 to June 30, 2015. The Other Opioid Group is comprised of immediate release
(IR) oxycodone, IR and extended release (ER) hydrocodone, IR and ER morphine, IR and ER hydromorphone, IR and ER tramadol, IR and ER oxymorphone, and IR and ER
tapentadol. The period of time indicated by shading was excluded from statistical analysis.
Source: IMS Government Solutions, Inc., a subsidiary of IMS Health, Inc., Danbury, CT.

Fig. 2. Relative change in rate of Intentional Abuse cases, Poison Center Program, 2009–2015. The Other Opioid Group is comprised of immediate release (IR) oxycodone, IR
and extended release (ER) hydrocodone, IR and ER morphine, IR and ER hydromorphone, IR and ER tramadol, IR and ER oxymorphone, and IR and ER tapentadol. The period
of time indicated by shading was excluded from statistical analysis. CI − 95% Conﬁdence intervals. (A) Rate adjusted for population. (B) Rate adjusted for prescription volume.
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The units-dispensed OxyContin rate decreased −56.1% (95% CI:
−62.7, −48.3) following reformulation, which was signiﬁcantly
greater than the Other Opioid group (−34.4%, 95% CI −39.6, −28.8).
3.3. Drug diversion program
A total of 4142 OxyContin cases and 57,135 Other Opioid cases
were received during the study period. The population adjusted
rate for OxyContin decreased −89.4% (95% CI: −92.4, −85.2) after
reformulation (Table 1, Fig. 3A). The decrease was greatest of the
opioid categories and statistically different than the Other Opioid
group (−26.8%, 95% CI: −36.0, −16.3). OxyContin rates declined
−8.9% (95% CI: −11.2, −6.5) each quarter following reformulation,
which was greater than the Other Opioid group (−2.8%, 95% CI:
−3.7, −1.9).
The prescription adjusted OxyContin rate decreased −85.8%
(95% CI: −89.7, −80.5) after reformulation (Table 1, Fig. 3B). The
decrease was greatest of the opioid categories and statistically
greater than the Other Opioid group (−31.7%, 95% CI: −40.3%,
−21.8). OxyContin rates declined −8.3% (95% CI: −10.6, −6.1) per
quarter after reformulation, which was signiﬁcantly greater than
the Other Opioid group (−3.6%, 95% CI: −3.6, −1.8).
The dosage unit adjusted rate for OxyContin decreased −83.4%
(95% CI: −88.0%, −76.0%) following reformulation, which was statistically greater than the Other Opioid group (−33.2%, 95% CI −42.1,
−23.0).
3.4. Opioid treatment program
A total of 8176 OxyContin cases and 15,873 Other Opioid
cases were received. The population adjusted rate for OxyContin
decreased −82.6% (95% CI: −86.7, −77.1) after reformulation from
baseline to 2015-Q2 (Table 1, Fig. 4A). The decrease was greatest
of the opioid categories and statistically greater than the Other
Opioid group (−32.0%, 95% CI: −40.1, −22.9). The OxyContin rate
declined −9.4% (95% CI: −11.1, −7.6) each quarter on average following reformulation, which was greater than the Other Opioid
group (−3.5%, 95% CI: −4.3, −2.7).
The prescription adjusted OxyContin rate decreased −72.8%
(95% CI: −80.6, −62.0) after reformulation from baseline to 2015-Q2
(Table 1, Fig. 4B). The decrease was greatest of the opioid categories
and statistically greater than the Other Opioid group (−30.9%, 95%
CI: −40.4, −19.8). OxyContin declined −8.2% (95% CI: −10.4, −6.0)
per quarter on average, which was greater than the Other Opioid
group (−3.2%, 95% CI: −4.2 to −2.3).
The units dispensed OxyContin rate decreased −68.4% (95% CI:
−77.5%, −55.7) following reformulation, which was signiﬁcantly
different than the Other Opioid group (−31.2%, 95% CI −41.4, −19.3)
lower than before the reformulation.
3.5. Survey of key informants’ patients program
A total of 3987 OxyContin cases OxyContin and 8451 Other Opioid cases were received. The population adjusted rate for OxyContin
decreased −53.9% (95% CI: −64.1, −40.7) after reformulation from
baseline to 2015-Q2 (Table 1, Fig. 5A). The decrease was greatest of
the opioid categories and statistically greater than the Other Opioid
group −7.2% (95% CI: −19.4, 6.9). OxyContin declined −4.0% (−5.5,
−2.4) each quarter on average following reformulation, which was
signiﬁcantly greater than the Other Opioid group (−1.5%, 95% CI:
−2.3, −0.7).
The prescription adjusted OxyContin rate decreased −34.8%
(95% CI: −48.4, −17.7) after reformulation from baseline to 2015Q2 (Table 1, Fig. 5B). The decrease was statistically greater than the
Other Opioid group (10.8% 95% CI: −5.1, 29.5) as well as the other
individual opioids, except morphine. OxyContin declined −2.6%
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(95% CI: −4.0 to −1.1) per quarter, which was signiﬁcantly greater
than the Other Opioid group (-0.3%, 95% CI: −1.1, 0.5).
The units dispensed adjusted OxyContin rate decreased −23.8%
(95% CI: −39.8, −3.6) following reformulation, which was statistically different than the Other Opioid group 9.0%, 95%CI (7.3, 28.3).
3.6. Route of administration
Of the 1863 OxyContin cases received from poison centers from
January, 2010 to June, 2015, 1511 reported the route of use: 1057
oral and 454 non-oral. Route was not reported for the remainder.
The rate of OxyContin abuse using for the oral route decreased
from 0.0285 per 100,000 population before reformulation to 0.0082
in 2015-Q2, a 71.0% (95% CI: −76.9, −63.7) reduction (Fig. 6).
The non-oral route decreased from 0.0184 per 100,000 population before reformulation to 0.0025 in 2015-Q2, an 86.7% (95% CI:
−91.9, −78.0) reduction, which was signiﬁcantly greater than the
oral route (p = 0.006).
3.7. Street price
A total of 3537 street price reports for OxyContin were submitted. The price of single-entity oxycodone, original formulation
OxyContin and reformulated OxyContin all decreased from 2011
through 2015. The geometric mean price of OxyContin original formulation decreased from $1.40 to $0.61 from 2011 to 2015, a 57%
(95% CI: 37% to 70%, p < 0.001) reduction. The geometric mean price
of reformulated OxyContin decreased from $0.89 to $0.53 from
2011 to 2015, a 41% (95% CI: 19%, 57%, p = 0.001) reduction. The
difference in price for original and reformulated OxyContin was
36% in 2011 and 13% in 2015 (Fig. 7).
4. Discussion
The introduction of abuse deterrent formulations has created
controversy regarding their value in reducing abuse of opioid analgesics. Concerns regarding abuse deterrent formulations involve 1)
the potential for overprescribing because prescribers may underestimate the abuse risk of an analgesic with abuse deterrent
properties, 2) dissemination of techniques to subvert an abuse
deterrent mechanism and thereby allow abuse to rebound or
increase, and 3) switching of abuse to other opioids or relying more
heavily on oral abuse.
Concerns about escalating prescribing of OxyContin are not supported by our results. After reformulation, the number of OxyContin
prescriptions dispensed decreased progressively over 5 years. This
change is notable because the prescription volume for OxyContin had increased greatly since its introduction in 1996. Other
investigators have documented a substantial decrease in OxyContin prescriptions following reformulation (Hwang et al., 2015;
Larochelle et al., 2015).
The sudden decrease in OxyContin prescriptions dispensed suggests that there was a sudden decrease in demand. While there
were likely other factors involved, a substantial decrease in a short
period limits the potential inﬂuence of other factors and suggests that abusers reduced their attempts to obtain OxyContin. For
most pharmaceuticals, the prescriber controls the supply of a drug,
but prescription opioids are unusual because abusers can stimulate prescription writing. A decrease in the number of attempts
to secure a prescription by feigning a painful condition (“doctor
shoppers”) could decrease the number of prescriptions dispensed,
particularly in the period immediately after reformulation. The subsequent long gradual decrease in prescribing seems more likely to
be inﬂuenced by factors in addition to doctor shopping, like restrictions implemented by insurers and perceptions by prescribers. Each
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Fig. 3. Relative change in rate of Diversion Cases, Drug Diversion Program, 2009–2015. The Other Opioid Group is comprised of immediate release (IR) oxycodone, IR and
extended release (ER) hydrocodone, IR and ER morphine, IR and ER hydromorphone, IR and ER tramadol, IR and ER oxymorphone, and IR and ER tapentadol. The period of
time indicated by shading was excluded from statistical analysis. CI − 95% Conﬁdence intervals. (A) Rate adjusted for population. (B) Rate adjusted for prescription volume.

of these reasons could potentially drive prescribers away from OxyContin and towards prescribing of other opioid analgesics.
In contrast to OxyContin, the number of prescriptions dispensed for the Other Opioid Group increased from 2010 to 2012,
then plateaued from 2012 to 2014, and ﬁnally decreased when
hydrocodone was reclassiﬁed as a Schedule 2 controlled substance.
Increased prescribing of prescription opioid analgesics is a legitimate concern, but prescription data do not indicate that OxyContin
has been affected.
We found that abuse and diversion of OxyContin as measured
by 4 programs decreased promptly and progressively over 5 years.
In addition, the street price for the reformulated product was
much lower than the original formulation. Other investigators have
reported substantial reductions in OxyContin abuse after reformulation. (Buer et al., 2014; Butler et al., 2013; Coplan et al., 2013;
Havens et al., 2014; Larochelle et al., 2015; Severtson et al., 2013;
Sessler et al., 2014), but included much shorter periods of evaluation after reformulation. Similarly, introduction of reformulated
OxyContin in Australia was followed by decreased prescribing,
abuse, injection and snorting (Degenhardt et al., 2015). A dissenting
view submitted to the FDA found that the endorsement of nonmedical use of OxyContin in the National Survey of Drug Use and
Health (NSDUH) did not differ between periods (one year before
and after its reformulation; Novak, 2013).However, this analysis
occurred soon after reformulation. Given the time needed for a

reformulated product to permeate the market, it is likely that the
original formulation was readily accessible for much of the analysis
period. Analysis of current data from NSDUH indicates trends similar to our results. After increasing from 2004 to 2010, endorsement
of past year nonmedical use of OxyContin decreased 23.7% from
2011 to 2014 (Fig. 8).
Our analytic models assumed a constant effect for other interventions that were enacted during the study period, such as
expansion of prescription drug monitoring plans (PDMPs), Risk
Evaluation and Mitigation Strategies (REMS), pill mill legislation,
and improved access to drug treatment, among many others.
Hence, there may be an interaction between reformulation, prevention initiatives and interventions, and prescribing practices. One
perspective to inform the extent of this limitation is to examine
demand for OxyContin. Our results suggest that the desirability of OxyContin decreased as indicated by concurrent decreased
prescription volume, decreased diversion and reduction in street
price. The street price of the original formulation fell 57% from
2011 to 2015. Furthermore, the Drug Diversion program found a
85.6% reduction in OxyContin diversion by 2015-Q2, so the price
decreased while diversion also decreased, suggesting markedly
reduced demand for OxyContin.
The decrease in price for the original formulation of OxyContin was unexpected since classic supply and demand theory would
indicate that a very desirable drug with decreased supply should
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Fig. 4. Relative change in rate of abuse endorsement, Opioid Treatment Program, 2009 − 2015The Other Opioid Group is comprised of immediate release (IR) oxycodone, IR
and extended release (ER) hydrocodone, IR and ER morphine, IR and ER hydromorphone, IR and ER tramadol, IR and ER oxymorphone, and IR and ER tapentadol. The period
of time indicated by shading was excluded from statistical analysis. CI − 95% Conﬁdence intervals. (A) Rate adjusted for population. (B) Rate adjusted for prescription volume.

result in a higher price. However, there are several factors that likely
undermined the price of the original formulation. First, it is likely
that buyers realized that the original formulation was no longer
produced and that there are many counterfeit products posing as
the original formulation. Also important is the growing availability
and affordability of potent heroin.
Overall, OxyContin demonstrated the greatest relative decrease
in rates of abuse and diversion of all opioid groups throughout
the study period. As importantly, the time course of change in
the various opioid groups was different. OxyContin prescriptions,
diversion, and abuse all decreased abruptly, within months or one
year after its reformulation depending on the program. The initial
steep decrease was followed by a more gradual decrease. During the
initial decrease, it is likely that there were no major confounders
acting to reduce diversion and abuse of OxyContin. There were
undoubtedly a multitude of small interventions like drug take-back
days and news stories in the popular press that may have affected
perceptions of prescription opioid abuse in general. However, to
our knowledge, no major interventions occurred in late 2010 or
early 2011 that would be expected to selectively decrease OxyContin diversion and abuse. Therefore, we conclude that the initial
decrease was largely caused by a decrease in abuse and diversion
caused by reformulation of OxyContin.
The possibility that these changes were caused by reformulation
is reinforced by the observed increase in prescriptions dispensed

as well as an increase in abuse and diversion for the Other Opioid
group from 2010 to 2012. After increasing, the Other Opioid group
then plateaued and decreased through mid-2015. This observation
suggests that prescribing patterns and abuse behaviors switched
initially toward the other opioid analgesics, primarily immediate
release oxycodone, hydromorphone and morphine before other
factors reduced the abuse of those products as well. This interpretation is supported by the fact that rates adjusted for population
showed the greatest increases, but rates adjusted for prescription
volume were less affected, indicating that abuse per unit of drug
did not increase substantially, just the amount of drug dispensed.
The route of abuse as represented by the Poison Center Program
indicates that both oral and non-oral routes of abuse decreased
although the decrease in non-oral abuse was greater. This result
may seem paradoxical as observers have predicted that ADFs
should affect primarily nasal insufﬂation or injection. (United States
Food and Drug Administration, 2015; Leece et al., 2015) The progression from swallowing to snorting or injection is often viewed
as unidirectional with snorting or injection displacing oral abuse.
However, research indicates most abusers endorse both oral and
non-oral use, perhaps depending on their desire and needs at the
time of abuse as well as the environment of abuse (Katz et al., 2011;
Surratt et al., 2011). Furthermore, most studies do not collect data
on chewing, which is a common form of tampering. In poison centers, chewing is classiﬁed as oral. Therefore, decreased abuse in a

226

S.G. Severtson et al. / Drug and Alcohol Dependence 168 (2016) 219–229

Fig. 5. Change in rate of abuse endorsement, Survey of Key Informant Patients, 2009–2015. The Other Opioid Group is comprised of immediate release (IR) oxycodone, IR
and extended release (ER) hydrocodone, IR and ER morphine, IR and ER hydromorphone, IR and ER tramadol, IR and ER oxymorphone, and IR and ER tapentadol. The period
of time indicated by shading was excluded from statistical analysis. CI − 95% Conﬁdence intervals. (A) Rate adjusted for population. (B) Rate adjusted for prescription volume.

Fig. 6. Change in route of exposure in poison center cases involving OxyContin after reformulation. The category of oral route includes swallowing tablet whole, dissolving
in mouth, and chewing then swallowing. Category of non-oral route includes injection or inhalation. The period of time indicated by shading was excluded from statistical
analysis.

non-oral route would be expected to reduce concomitant use by
swallowing intact or chewing and swallowing, which would then
reduce the number of oral abuse events as well.

Our analysis has several limitations. Morphine extended release
has been proposed as an appropriate comparator for oxycodone
extended release because it comprises a large part of the extended
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Fig. 7. Reported street price trends of oxycodone products on StreetRx.com.
SE = single entity. IR = immediate release formulations.

release opioid market. We chose a compound endpoint of the group
of Other Opioids because morphine alone is a poor choice for a
comparator. The primary concern is that abusers identify immediate release oxycodone, hydromorphone, and oxymorphone, rather
than morphine, as the drugs they use when OxyContin is not available (Cicero and Ellis, 2015). Also important is the fact that the
morphine market is highly inﬂuenced in recent years by increased
in low-abuse risk populations because it is increasingly required by
health plans to be used before OxyContin. Since OxyContin abusers
have reported switching to a variety of prescription opioid analgesics, we concluded that the most defensible position is to include
all of the opioids together and then to break out the major generic
categories for investigators to interpret for themselves.
Another limitation of the poison center and street price data
is spontaneous reporting. Various factors may inﬂuence the decision for someone to contact these programs. Data from the Poison
Center, Opioid Treatment, Survey of Key Informants’ Patients and
StreetRx programs are based on self-reported information with all
the limitations inherent to that process such as misidentiﬁcation
by the abuser. The extent of this misidentiﬁcation is unknown, but
is the lowest for the Drug Diversion program because the investigator often has the tablet for identiﬁcation. These biases are not
thought to vary substantially over time. Each program has been in
operation for many years and there were not changes in the programs that coincided with decreased rates of OxyContin diversion
or abuse. Furthermore, the trends from these programs have lasted
for 5 years, have substantial magnitude and are consistent with
our data from treatment programs and with the medical literature.
Nevertheless, the potential for confounding is present.
Despite methods to circumvent the abuse deterrent mechanism,
abuse and diversion of OxyContin decreased promptly following
the introduction of a crush- and solubility- resistant formulation
and continued to decrease over the subsequent 5 years. Part of
the response may be explained by a general decrease in abuse and
diversion of opioid analgesics in general. The temporal proﬁle of an
abrupt decrease in prescription volume and rates of diversion and
abuse as well as supporting evidence of decreased non-oral abuse
and street price and similar results in the medical literature support the conclusion that the reformulation of OxyContin decreased
its abuse and diversion.
There are currently few products with FDA-approved labeling that includes statements about abuse deterrent properties. Of
these, only OxyContin has a sufﬁcient number of dispensed prescriptions to measure it in postmarketing surveillance systems.
Essentially all data from several sources indicate it’s effectiveness
in reducing diversion and abuse of OxyContin itself. It may have
an effect on the abuse of extended release opioid analgesics as a
group since those products are also experiencing a decrease (Dart
et al., 2015). However, the effect on overall abuse of all opioid
analgesics is unlikely to be measurable because extended release

Fig. 8. Trends of Endorsement for past year nonmedical use of OxyContin in
National Survey of Drug Use and Health.
The number of past year endorsements for each year are plotted by year:
2004–2014. The vertical line indicates introduction of reformulated OxyContin.
2013:
http://archive.samhsa.gov/data/NSDUH/2013SummNatFindDetTables/
DetTabs/NSDUH-DetTabsSect1peTabs1to46-2013.htm#tab1.1a, page 120
http://archive.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/
2012:
DetTabs/NSDUH-DetTabsSect1peTabs1to46-2012.htm#Tab1.1A
2011:
http://archive.samhsa.gov/data/NSDUH/2011SummNatFindDetTables/
NSDUH-DetTabsPDFWHTML2011/2k11DetailedTabs/Web/HTML/NSDUHDetTabsSect1peTabs1to46-2011.htm#Tab1.1A
2010:
http://archive.samhsa.gov/data/NSDUH/2k10ResultsTables/
NSDUHTables2010R/HTM/Sect1peTabs1to46.htm#Tab1.1A
2009:
http://archive.samhsa.gov/data/NSDUH/2k10ResultsTables/
NSDUHTables2009R/HTM/Sect1peTabs1to46.htm#Tab1.1A
2008:
http://archive.samhsa.gov/data/NSDUH/2k10ResultsTables/
NSDUHTables2008R/HTM/Sect1peTabs1to46.htm#Tab1.1A
2007:
http://archive.samhsa.gov/data/NSDUH/2k10ResultsTables/
NSDUHTables2007R/HTM/Sect1peTabs1to46.htm#Tab1.1A
2006:
http://archive.samhsa.gov/data/NSDUH/2k10ResultsTables/
NSDUHTables2006R/HTM/Sect1peTabs1to46.htm#Tab1.1A
2005: http://archive.samhsa.gov/data/NSDUH/2k5nsduh/tabs/Sect1peTabs1to66.
htm#Tab1.1A
2004:
http://archive.samhsa.gov/data/NSDUH/2k4nsduh/2k4tabs/
Sect1peTabs1to66.htm#tab1.1a
Data were obtained from the detailed tables published by Substance Abuse and
Mental Health Services Administration for 2010–2014:

opioids represent a small part of the opioid market. In order to properly understand the impact of abuse deterrent opioids, most of the
opioid market needs to be comprised of ADF products.
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